BWBao-Zhong Wang

Bao-Zhong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bao-Zhong Wang has a total of 223 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery

    by Rui Jin, Bao-Zhong Wang, Wandi Zhu

    Respiratory mucosal vaccination can induce robust humoral and cellular immune responses, as well as effective mucosal immunity at the primary site of pathogen entry, and has been shown to provide superior protection against respiratory viral infections compared with traditional approaches. Among current vaccine technologies, mRNA vaccines offer unique advantages, including rapid development, flexible antigen design, and potent immunogenicity. However, efficient mucosal delivery of mRNA remains challenging due to biological barriers within the respiratory tract, including mucus clearance, limited cellular uptake, and instability during aerosolization. Furthermore, mRNA formulations intended for respiratory mucosal delivery require more stringent safety and tolerability profiles. Recent advances in nanoparticle engineering have accelerated the development of mRNA delivery systems optimized for respiratory mucosal immunization. This review aims to evaluate how nanoparticle engineering strategies can overcome respiratory mucosal barriers and improve the safety, stability, delivery efficiency, extrahepatic expression, and immunogenicity of mRNA vaccines and therapeutics. We summarize recent progress in engineered mRNA nanoparticle platforms for respiratory mucosal immunity, encompassing modified lipid nanoparticles (LNPs), polymer-based mRNA nanoparticles, and hybrid nanoparticle systems, including lipid-inorganic, polymeric hybrid, and lipid-extracellular vesicle (EV) nanoparticles. We further discuss optimization strategies for mucosal mRNA delivery, including the incorporation of appropriate adjuvants, the development of polyethylene glycol (PEG) alternatives, and advanced delivery approaches. Finally, we highlight current challenges and future directions for the rational design of next-generation mRNA nanoparticle platforms that can induce durable and broadly protective mucosal immunity against respiratory viral infections.


  • mRNA Vaccines for Influenza: Hope for a Universal Vaccine?

    by Priscilla Omotara, Wandi Zhu, Bao-Zhong Wang

    Seasonal influenza epidemics and pandemics remain a persistent public health threat. A universal influenza vaccine is urgently needed. Such a vaccine must accommodate rapid viral evolution, strain diversity-including types A and B and their many subtypes-and the complexities of human immune history and biases. Messenger RNA (mRNA)-formulated lipid-nanoparticles have evolved from an emergency pandemic vaccine experiment into a versatile vaccine platform. This technology has demonstrated potential to address several critical challenges in developing a universal influenza vaccine, including rapid strain updates, the production of high-valent formulations, and the ability to target conserved antigens that may induce broader and longer-lasting protection. This review summarizes recent studies and applications of multivalent antigen selection strategies and self-amplifying and circular RNA vaccine platforms to develop mRNA influenza vaccines to achieve vaccine universality, with an emphasis on immune responses against conserved targets. We also review the latest advances in generating long-term mucosal immunity against influenza through optimized mRNA delivery. Finally, we discuss practical considerations for correlates of protection, manufacturing, and accessibility, pioneering mRNA vaccine candidates heading to clinical trials, and milestones that define vaccine "universality."


  • Open Access

    Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunity

    by Ki-Hye Kim, Hye Suk Hwang, Surya Sekhar Pal, Chau Thuy Tien Le, Phillip Grovenstein, Mahmuda Yeasmin, Jae Min Song, Young-Man Kwon, Baozhong Wang, Sang-Moo Kang

    Type I interferons (IFNs) are critical for early antiviral defense, yet their role in shaping vaccine-induced immunity remains incompletely understood. Here, we investigated the impact of type I IFN receptor (IFNαβR) deficiency on immune responses to influenza virus infection and vaccination in IFNαβR-deficient (AB6) mice. AB6 mice exhibited profound susceptibility to influenza virus infection, characterized by accelerated weight loss, elevated lung viral loads, and severe histopathology. Despite inducing short-term IgG antibodies and protection against weight loss after H5 hemagglutinin virus-like particle (H5 VLP) vaccination, AB6 mice were less effective in controlling lung viral loads and inflammation after lethal influenza virus infection, compared to the wild-type (B6) mice. IFNαβR deficiency dysregulated chemokines and numerous innate immune cells, particularly neutrophils, contributing to lung pathology after H5 VLP vaccination and influenza virus infection. AB6 mice exhibited a faster kinetics of waning IgG antibodies and lower efficacy of long-term protection after vaccination than wild-type B6 mice. IMPORTANCE: Type I interferons (IFNs) are essential mediators of antiviral defense, but their contribution to vaccine-induced immunity remains unclear. This study reveals that type I IFN receptor signaling is dispensable for the initial antibody induction but is critical for sustaining long-term humoral immunity and balanced immune regulation after influenza vaccination and infection. Loss of IFNαβR signaling leads to impaired viral control, excessive neutrophil-driven inflammation, and disrupted immune cell homeostasis. These findings highlight type I IFN signaling as a key integrator of innate and adaptive immune responses required for adequate and durable antiviral protection.


  • Open Access

    Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection

    by Wandi Zhu, Lai Wei, Chunhong Dong, Joo Kyung Kim, Madeline Bruhn, Yao Ma, Alex Ferrante, Arini Arsana, Priscilla Omotara, Sang-Moo Kang, et al.

    Developing innovative vaccine platforms and delivery strategies to induce broad, protective immunity in the respiratory tract is crucial for preventing influenza infection and transmission in potential epidemics and pandemics. In this study, we used cell-derived extracellular vesicles (EVs) as a vaccine platform to display mosaic human and avian influenza hemagglutinins (HAs) concurrently, including HA1/HA9/HA12 or HA3/HA4/HA10, on the EV surfaces. Immunization with the mosaic HA-EV vaccine elicited cross-reactive antibodies against influenza HA stalks and viruses, robust virus-specific cellular immune responses, and a balanced Th1/Th2 immune profile. Notably, the EVs demonstrated a promising application as an effective mucosal vaccine strategy, as evidenced by enhanced HA stalk- and virus-specific IgA in mucosal tissues and complete protection against heterosubtypic reassortant H7N9 and H5N1 virus infections in mice via intranasal immunization. EV-based mosaic HA vaccines hold great promise for developing universal influenza vaccines that target a mucosal route.


  • Open Access

    Mature Dendritic Cell-Derived Extracellular Vesicles are Potent Mucosal Adjuvants for Influenza Hemagglutinin Vaccines

    by Chunhong Dong, Lai Wei, Wandi Zhu, Joo Kyung Kim, Ye Wang, Priscilla Omotara, Arini Arsana, Bao-Zhong Wang

    Immune cell-derived extracellular vesicles (EVs) possess intrinsic immunomodulatory properties, making them potential vaccine adjuvants. Here, we show that EVs from mature bone marrow-derived dendritic cells (mDC-EVs), rather than those from immature dendritic cells (imDC-EVs), are potent mucosal adjuvants for influenza hemagglutinin (HA) vaccines. In vitro, mDC-EVs exhibited intriguing immune-stimulating effects on various antigen-presenting cells, including DCs, macrophages, and B cells. Furthermore, intranasal immunization with mDC-EVs-adjuvanted A/Aichi/2/1968 (H3N2) HA (H3+mDC-EVs) significantly enhanced and expanded both systemic and mucosal antibody and cellular immune responses in female Balb/c mice. These responses offered complete protection against bodyweight loss following homologous and heterologous virus challenges. Mechanistically, H3+mDC-EVs immunization promoted enhanced airway immune cell recruitment, distinct antigen cellular uptake, and rapid activation of B and T cells within 24 h. It also induced robust germinal center reactions and antigen-experienced memory T-cell responses in lung-draining mediastinal lymph nodes 14 days postimmunization. Given their biocompatibility and solid adjuvanticity, mDC-EVs represent a promising adjuvant candidate for mucosal vaccine development.


  • Open Access

    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination

    by Chau Thuy Tien Le, Ki-Hye Kim, Jannatul Ruhan Raha, Noopur Bhatnagar, Surya Sekhar Pal, Phillip Grovenstein, Mahmuda Yeasmin, Rong Liu, Bao-Zhong Wang, Sang-Moo Kang

    The current influenza vaccine is based on immunity to hemagglutinin (HA) and provides poor cross-protection. Here, we generated mRNA vaccine encoding influenza B virus (IBV) neuraminidase (NA) conjugated to influenza A virus M2 ectodomain (M2e), encapsulated in lipid nanoparticles (LNP), capable of inducing cross-lineage IBV protection in a dose-dependent pattern. The combination of low-dose NA mRNA and inactivated split IBV vaccines was found to induce significantly higher levels of cross-reactive IgG responses, NA and HA inhibition titers, effector and memory cellular immune responses as well as cross-lineage protection than either NA mRNA or split vaccine alone. This study suggests that the NA mRNA vaccine not only provides cross-lineage protection with a high dose but also enhances the cross-protective efficacy of the combined low-dose NA mRNA and split vaccines. Our findings support a new strategy of using mRNA LNP-supplemented conventional vaccination to enhance cross-protection. IMPORTANCE: This study highlights a significant advancement in influenza vaccination strategies. To test a new vaccination strategy, we developed an influenza B virus (IBV) neuraminidase (NA) mRNA vaccine which could provide cross-lineage protection at a high dose. More importantly, the co-administration of NA mRNA and split IBV vaccine at low doses was found to significantly enhance the hemagglutinin and NA immunity as well as cross-lineage protection of seasonal IBV vaccines. This proof-of-concept study provides evidence for a novel strategy to enhance the immunogenicity and cross-protective efficacy of conventional vaccines by supplementing with new targets of mRNA vaccines.


  • Open Access

    Inverted HA-EV immunization elicits stalk-specific influenza immunity and cross-protection in mice

    by Wandi Zhu, Chunhong Dong, Lai Wei, Joo Kyung Kim, Bao-Zhong Wang


  • Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice

    by Yao Ma, Chunhong Dong, Joo Kyung Kim, Wandi Zhu, Lai Wei, Ye Wang, Sang-Moo Kang, Bao-Zhong Wang


  • Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice

    by Lai Wei, Wandi Zhu, Chunhong Dong, Joo Kyung Kim, Yao Ma, Timothy L. Denning, Sang-Moo Kang, Bao-Zhong Wang


  • Open Access

    Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice

    by Joo Kyung Kim, Wandi Zhu, Chunhong Dong, Lai Wei, Yao Ma, Timothy Denning, Sang-Moo Kang, Bao-Zhong Wang

    Intranasal immunization with HA3-tFliC/NP SDAD protein nanoparticles enhances both systemic and mucosal immunity, promoting influenza cross-protection. Sequential priming immunization further enhances GC B cells, Tfh cells, and effector T cells.